HEPATITIS DELTA EPIDEMIOLOGY IN ROMANIA



Romania

- Located in Eastern Europe
- Population: 19.053.815
- 52.2% urban population



- In 2015 a multicenter study was conducted among chronically HBV infected (HBsAg-positive) adult patients (age ≥18 years) in 10 Gastroenterology /Infectious Diseases centers covering approximately 80-90% of population from all geographical regions of our country.
- 2761 HBsAg positive patients included

Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Trifan A, Grigorescu M, Motoc A, Suceveanu A, Curescu M, Caruntu F, Sporea I, Brisc C, Rogoveanu I, Cerban R, Tugui L, Alexandrescu A. Hepatitis Delta Virus Infection in Romania: Prevalence and Risk Factors. J Gastrointestin Liver Dis. 2015 Dec;24(4):413-21. doi: 10.15403/jgld.2014.1121.244.dtv. PMID: 26697566.

Epidemiology

- The prevalence of chronic HBV infection (HBsAg positivity) in adult population in Romania is 4.4%, which means an estimated number of 650,000 infected people
- The overall prevalence of anti-HDV IgG antibodies in HBsAg-positive patients was 23.1% (95%CI: 21.4-25.0 %; N=639)
- Patients with detectable HDV RNA represented 16.4% (N=454) from the total HBsAg-positive cohort.

Epidemiology

By age group:

- 18-29 18.6%
- 30-39 **–** 16.9%
- 40-49 21.9%
- 50-59 28.9%
- Over 60 24.8%

On average, patients with HDV infection from our study tend to be older, more female and urban residents, and the virological profile of helper virus is HBeAg-negative with an undetectable/low HBV viral load

Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Trifan A, Grigorescu M, Motoc A, Suceveanu A, Curescu M, Caruntu F, Sporea I, Brisc C, Rogoveanu I, Cerban R, Tugui L, Alexandrescu A. Hepatitis Delta Virus Infection in Romania: Prevalence and Risk Factors. J Gastrointestin Liver Dis. 2015 Dec;24(4):413-21. doi: 10.15403/jgld.2014.1121.244.dtv. PMID: 26697566.

Severity


- There was a significantly higher percentage of patients with liver cirrhosis vs chronic hepatitis within the HBV-HDV coinfection group (43.4% vs 19.0%, p=0.0001)
- Within the group with HBV-HDV, patients with active delta infection (positive viral load) had a higher risk of liver cirrhosis (34.3% vs 12.7%, p=0.0001).

Current available treatment — HBV/HDV — NHI supported

- HBV ETV
 - TFV
 - Pegasys

- HDV: Pegasys 96 weeks RGD.
- Bulevirtide to be available starting AUG/SEP 2023 supported by NHI

Personal experience



Patients obtaining undetectable RNA and patients continuing treatment (more than 1 log drop in HDV RNA)

OUTCOMES OF RESPONSE GUIDED THERAPY WITH PEGYLATED INTERFERON ALPHA 2A IN CHRONIC HEPATITIS B AND D, G.S. Gherlan, et al. Journal of Hepatology, Volume 70, Issue 1, e465, EASL – The Liver Congress, Vienna, Austria, April 10-14, 2019.